Company Description
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.
In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease.
The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 15, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 124 |
| CEO | Henry O. Gosebruch |
Contact Details
Address: 490 Arsenal Way, Suite 200 Watertown, Massachusetts 02472 United States | |
| Phone | (857) 760-0900 |
| Website | neumoratx.com |
Stock Details
| Ticker Symbol | NMRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001885522 |
| CUSIP Number | 640979100 |
| ISIN Number | US6409791000 |
| Employer ID | 84-4367680 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Paul L. Berns | Co-Founder and Executive Chairman |
| Joshua Pinto Ph.D. | Chief Financial Officer and Treasurer |
| Henry O. Gosebruch | President, Chief Executive Officer and Director |
| Carol Suh | Co-Founder and Chief Operating Officer |
| Dr. Robert Michael Poole FACP, M.D. | Co-Founder and Advisor |
| Michael Lee Milligan | Principal Accounting Officer |
| Dr. Rajesh Manchanda Ph.D. | Chief Technical Operations Officer |
| Nicholas Brandon Ph.D. | Chief Scientific Officer |
| Jason G. Duncan | Chief Legal Officer |
| Amy Sullivan | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2024 | 8-K | Current Report |
| Mar 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 7, 2024 | 10-K | Annual Report |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |